Business Standard

Analysts' corner

NTPC, Power Grid Corp, Dabur India & Divis Laboratories

Related News


Reco price/date: Rs 147/June 15
Current/target price: Rs 147/Rs 158
NTPC Ltd has commissioned the unit 3 (660 Mw) of Sipat Super Thermal Power Station stage-I on June 2. With this, the total capacity of NTPC has become 38,674 Mw. The company targets to add 4,160 Mw of capacity in FY13 and has till date added 1,660 Mw this financial year. At current market price, the stock is trading at 1.4 times FY13 estimated and 1.3 times FY14 estimated price/book value. Maintain accumulate.

Angel Broking

POWER GRID CORP
Reco price/date: Rs 104/June 4
Current/target price: Rs 105/Rs 125
Powergrid Corp of India Ltd’s (PGCIL) FY12 results corroborate its ability to deliver strong execution growth, which was 35 per cent ahead of analysts’ estimates and up 97 per cent year-on-year, driving up return ratios. Notwithstanding emerging concerns on new capex growth, owing to a slowdown in generation capex, analysts believe PGCIL is geared to maintain its earnings CAGR (compound annual growth rate) of 21 per cent and asset CAGR of 24 per cent over next three years. Thanks to the new transmission pricing formulae, favourable regulatory policies reaffirm PGCIL’s strong bargaining power. Maintain Buy.

Deutsche Bank Markets Research

DABUR INDIA
Reco price/date: Rs 103/June 4
Current/target price: Rs 102/Rs 125
With the launch of ‘Dabur Uveda Sunblock Cream SPF 30’, Ltd has entered the Rs 240-crore sun-protection market. The new launch is a premium product and indicates Dabur’s focus on its skin care portfolio. Also, it has a unique water-resistant formula. Analysts believe marked step-up in new launches in FY13 and funneling gross margin expansion to ad spend are likely to aid volume growth for Dabur. The stock has corrected nine per cent after the March quarter results were announced, in spite of improving volume growth (9.5 per cent, eight per cent and five per cent in Q4, Q3 and Q2’FY12, respectively). Maintain Buy.

Edelweiss Securities

DIVIS LABORATORIES
Reco price/date: Rs 925/June 5
Current/target price: Rs 934/Rs 1,107
Analysts believe Ltd is likely to sustain its high growth rates of over 25 per cent, best-in-class margins (37-39 per cent Ebitda— earnings before interest, taxes, depreciation, and amortisation) and superior return ratios. A strong base of a stellar FY12 will not tame growth in FY13. Management has guided for 25 per cent growth in constant currency terms, with upside risks from rupee depreciation. Additional capex plans enhance confidence given the company’s commitment to capital efficiency (capacities hardly remain idle at Divis). IIFL has raised its estimate for FY13-14 core earnings by 8-10 per cent. Maintain Buy.

IIFL

Read more on:   
|
|
|

Read More

Today`s pick

The index-range-traded between 5,125 and 5,200 and closed weak.

Quick Links

 

Market News

Raising the output key to Cairn India's prospects

With crude oil prices benign, increasing oil and gas production is crucial to drive growth

Biocon sees muted quarter, lacks immediate triggers

Reduced exports to West Asia & North Africa, capacity constraints affect sales

Exchanges plan stake sales in depository arms

NSE in talks with investors for offloading stake, BSE considering an IPO; to do so before April

Many listed firms had same auditors for over 10 yrs: IIAS

Proxy advisory body Institutional Investor Advisory Services India (IIAS) has called for periodic rotation of auditors and capping their tenure ...

Freeing diesel : Profound effect across many industries

The decontrol of diesel over the weekend will have a profound effect on the oil industry value chain. It could significantly reduce the fiscal ...

Back to Top